XBiotech’s True Human monoclonal antibody, which blocks pathologic inflammatory responses, is being developed to treat diseases such as cancer, atherosclerosis and diabetes. C3i provides a solution to meet
Relovair is a once-daily inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combination treatment, comprising fluticasone furoate and vilanterol (FF/VI), currently under development for the treatment of COPD and asthma. The
The agreement covers nine neglected tropical diseases (NTDs) – kinetoplastid diseases (leishmaniass, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis) and dracunculiasis,
Gene expression data from human tumor samples indicate that both CSN5 and WEE1 genes promote tumor cell growth and cancer pathogenesis. WEE1 is a tyrosine kinase that regulates
Now with 451 kinase assays in the scanMAX assay panel, which will be available for global customers by mid-June 2011, DiscoveRx will continue to offer kinase panel for
PF-01367338, an oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, is currently in Phase 1/2 development for solid tumors. The program is supplemented by two ongoing trials, currently
Patient enrollment was completed in May 2011, recruiting over 1,400 patients at 180 sites in the US, Europe, Central Eastern Europe and Israel. The primary endpoint of the
YERVOY is a recombinant, human monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), a negative regulator of T-cell activation. The US Food and Drug Administration approved
BioVigilant claims its IMD-A 300 and IMD-A 350 systems can detect immediately the presence of bacteria in the drug manufacturing process, in contrast to traditional growth methods. Based
Schiff Nutrition International develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the US and throughout the world. The agreement allows
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.